The next generation cancer therapeutics and autoimmune disease were developed by Sutro Biopharma. This company has pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. Their focus is aimed primarily on Antibody Conjugates, Bispecific Antibodies and cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, the company can design and develop targeted medicines by innovating outside the constraints of the cell. The company technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency. Their approach to discovery, without the cell, is also transcending the limitations of biologics manufacturing.